Truxal, 25 mg 100 pcs

Truxal is a neuroleptic, a derivative of thioxanthene. It has antipsychotic, pronounced sedative and moderate antidepressant effect.

Pharmacodynamics

The antipsychotic action of Truxal is associated with its blocking effect on dopamine receptors. Blockade of these receptors is also associated with antiemetic and analgesic properties of the drug. Truxal is able to block 5-NT< sub>2 – receptors, α< sub>1 – adrenoreceptors, and H< sub>1 – histamine receptors, which determines its adrenoblocking, hypotensive and antihistamine properties.

Pharmacokinetics

The bioavailability of chlorprotixen with oral administration is about 12%. Chlorprotixen is rapidly absorbed from the intestine, maximum serum concentration is reached after 2 hours. The elimination half-life is about 16 hours. Chlorprotixene penetrates the placental barrier and is excreted in small amounts with breast milk. Metabolites have no neuroleptic activity and are excreted with feces and urine.

Indications

Truxal is a sedative antipsychotic with a wide range of indications, which include:

psychoses, including schizophrenia and manic states, occurring with psychomotor agitation, agitation and anxiety,
hangover withdrawal syndrome due to alcoholism and drug addiction,
hyperactivity, irritability, agitation, confusion in elderly patients,
behavioral disorders in children,
depressive states, neuroses, psychosomatic disorders,
insomnia,
pain (in combination with analgesics).

Pharmacological effect

Truxal is an antipsychotic, a thioxanthene derivative. It has antipsychotic, pronounced sedative and moderate antidepressant effects.

Pharmacodynamics

The antipsychotic effect of Truxal is associated with its blocking effect on dopamine receptors. The antiemetic and analgesic properties of the drug are also associated with the blockade of these receptors. Truxal is able to block 5-HT2 receptors, α1 adrenergic receptors, as well as H1 histamine receptors, which determines its adrenergic blocking, hypotensive and antihistamine properties.

Pharmacokinetics

The bioavailability of chlorprothixene when taken orally is about 12%. Chlorprothixene is rapidly absorbed from the intestine, the maximum concentration in the blood serum is reached after 2 hours. The half-life is approximately 16 hours. Chlorprothixene crosses the placental barrier and is excreted in small quantities in breast milk. Metabolites do not have neuroleptic activity and are excreted in feces and urine.

Special instructions

Truxal should be prescribed with caution to patients suffering from epilepsy, parkinsonism, with severe cerebral atherosclerosis, with a tendency to collapse, with severe cardiovascular and respiratory failure, with severe impaired liver and kidney function, diabetes mellitus, prostate hypertrophy.

The use of Truxal can lead to a false positive result when conducting an immunobiological urine test for pregnancy, a false increase in the level of bilirubin in the blood, and a change in the QT interval on the electrocardiogram.

During treatment with Truxal, it is recommended to refrain from drinking alcohol and avoid increased sun exposure.

Taking Truxal has a negative effect on activities that require a high speed of mental and physical reactions (for example, driving vehicles, servicing machines, working at heights, etc.).

Active ingredient

Chlorprothixene

Composition

Active ingredient:

chlorprothixene hydrochloride 25 mg;

Excipients:

corn starch,

lactose monohydrate,

copovidon,

glycerol 85%,

microcrystalline cellulose,

sodium croscarmellose,

talc,

magnesium stearate;

Film shell composition:

Opadry OY-S-9478 brown (E 172; E 171) RM 1030;

Contraindications

CNS depression of any origin (including those caused by alcohol, barbiturates or opiates), coma, vascular collapse, diseases of the hematopoietic organs, pheochromocytoma.
Hypersensitivity to the components of the drug.
Truxal should, if possible, not be prescribed to pregnant women or during breastfeeding.

Side Effects

Drowsiness, tachycardia, dry mouth, increased sweating or difficulty in accommodation. These side effects, which usually occur early in therapy, often disappear as therapy continues. Orthostatic hypotension may occur, especially when using Truxal in high dosages.

Dizziness, dysmenorrhea, skin rashes, and constipation are rare. Extrapyramidal symptoms are especially rare.

Isolated cases of a decrease in the convulsive threshold, the occurrence of transient benign leukopenia and hemolytic anemia have been described. With long-term use, especially in high doses, the following may be observed: cholestatic jaundice, galactorrhea, gynecomastia, weakened potency and libido, increased appetite, weight gain.

Interaction

The inhibitory effect of chlorprothixene on the central nervous system may be enhanced when taken simultaneously with ethanol and ethanol-containing drugs, anesthetics, opioid analgesics, sedatives, hypnotics, and neuroleptics.

The anticholinergic effect of chlorprothixene is enhanced by the simultaneous use of anticholinergic, antihistamine and antiparkinsonian drugs.

The drug enhances the effect of antihypertensive drugs.
The simultaneous use of chlorprothixene and adrenaline can lead to arterial hypotension and tachycardia.

The use of chlorprothixene leads to a decrease in the threshold of convulsive activity, which requires additional adjustment of the dose of antiepileptic drugs in patients with epilepsy.

The ability of chlorprothixene to block dopamine receptors reduces the effectiveness of levodopa.

Extrapyramidal disorders may occur with the simultaneous use of phenothiazines, metoclopramide, haloperidol, and reserpine.

Overdose

Symptoms. Drowsiness, hypo- or hyperthermia, extrapyramidal symptoms, convulsions, shock, coma.

Treatment. Symptomatic and supportive. Gastric lavage should be performed as quickly as possible, and the use of a sorbent is recommended.

Measures should be taken to maintain the functioning of the respiratory and cardiovascular systems. Adrenaline should not be used because this may lead to a subsequent decrease in blood pressure.

Seizures can be treated with diazepam, and extrapyramidal symptoms with biperiden.

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

5 years

Manufacturer

H. Lundbeck A/O, Denmark